{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:26:42Z","timestamp":1792762002135,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,14]],"date-time":"2015-09-14T00:00:00Z","timestamp":1442188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech, Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","jacionline.org","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.jaci.2015.08.023","type":"journal-article","created":{"date-parts":[[2015,10,24]],"date-time":"2015-10-24T18:08:52Z","timestamp":1445710132000},"page":"474-481","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":175,"title":["Timing and duration of omalizumab response in patients with chronic idiopathic\/spontaneous urticaria"],"prefix":"10.1016","volume":"137","author":[{"given":"Allen","family":"Kaplan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeniya","family":"Antonova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Trzaskoma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Raimundo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Ros\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore A.","family":"Omachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Zazzali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2015.08.023_bib1","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1398-9995.2010.02496.x","article-title":"Unmet clinical needs in chronic spontaneous urticaria. A\u00a0GA2LEN task force report","volume":"66","author":"Maurer","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2015.08.023_bib2","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/all.12313","article-title":"The EAACI\/GA2LEN\/EDF\/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update","volume":"69","author":"Zuberbier","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2015.08.023_bib3","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.jaci.2014.02.036","article-title":"The diagnosis and management of acute and chronic urticaria: 2014 update","volume":"133","author":"Bernstein","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2015.08.023_bib4","first-page":"214","article-title":"Epidemiology of urticaria in Spain","volume":"14","author":"Gaig","year":"2004","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaci.2015.08.023_bib5","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/j.1365-2230.2010.03840.x","article-title":"Epidemiology of urticaria: a representative cross-sectional population survey","volume":"35","author":"Zuberbier","year":"2010","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaci.2015.08.023_bib6","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1365-2133.2005.06976.x","article-title":"Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity","volume":"154","author":"Staubach","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2015.08.023_bib7","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/j.1398-9995.2005.00833.x","article-title":"A\u00a0new tool to evaluate the impact of chronic urticaria on quality of life: Chronic\u00a0Urticaria Quality of Life Questionnaire (CU-QoL)","volume":"60","author":"Baiardini","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2015.08.023_bib8","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2133.1997.tb14895.x","article-title":"The impact of chronic urticaria on the quality of life","volume":"136","author":"O'Donnell","year":"1997","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2015.08.023_bib9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2013.05.013","article-title":"Omalizumab in patients with symptomatic chronic idiopathic\/spontaneous urticaria despite standard combination therapy","volume":"132","author":"Kaplan","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2015.08.023_bib10","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2015.08.023_bib11","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/jid.2014.512","article-title":"Efficacy and safety of omalizumab in patients with chronic idiopathic\/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study","volume":"135","author":"Saini","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2015.08.023_bib12","doi-asserted-by":"crossref","unstructured":"Flood E, Devlen J, Zazzali JL. PRS53 test-retest reliability of the Urticaria Patient Daily Diary in electronic format among adults and adolescents. Poster presented at: 17th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research; June 2-6, 2012; Washington, DC.","DOI":"10.1016\/j.jval.2012.03.337"},{"key":"10.1016\/j.jaci.2015.08.023_bib13","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.anai.2010.06.011","article-title":"Development of a daily diary for patients with chronic idiopathic urticaria","volume":"105","author":"Mathias","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2015.08.023_bib14","doi-asserted-by":"crossref","first-page":"186","DOI":"10.2500\/aap.2012.33.3508","article-title":"Adaptation and validation of the Urticaria Patient Daily Diary for adolescents","volume":"33","author":"Mathias","year":"2012","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaci.2015.08.023_bib15","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jaip.2015.04.015","article-title":"Similar efficacy with omalizumab in chronic idiopathic\/spontaneous urticaria despite different background therapy","volume":"3","author":"Casale","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2015.08.023_bib16","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jaci.2003.11.044","article-title":"Omalizumab rapidly decreases nasal allergic response and Fc\u03b5RI on basophils","volume":"113","author":"Lin","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2015.08.023_bib17","first-page":"38","article-title":"Longitudinal study of the expression of Fc\u03b5RI and IgE on basophils and dendritic cells in association with basophil function in two patients with severe allergic asthma treated with omalizumab","volume":"47","author":"Pereira Santos","year":"2015","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2015.08.023_bib18","first-page":"S30","article-title":"Omalizumab normalizes levels of high affinity immunoglobulin E receptor-positive skin mast cells in patients with chronic spontaneous urticaria: a randomized, double-blind, placebo-controlled study","volume":"134","author":"Metz","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2015.08.023_bib19","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.jaci.2013.10.015","article-title":"An algorithm for treating chronic urticaria with omalizumab: dose interval should be individualized","volume":"133","author":"Uysal","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2015.08.023_bib20","first-page":"37","article-title":"Why medication adherence matters to patients, payers, providers","volume":"22","author":"Stefanacci","year":"2013","journal-title":"Manag Care"},{"key":"10.1016\/j.jaci.2015.08.023_bib21","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jaci.2011.06.010","article-title":"A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria","volume":"128","author":"Saini","year":"2011","journal-title":"J Allergy Clin Immunol"}],"updated-by":[{"DOI":"10.1016\/j.jaci.2016.03.003","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000}}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674915012476?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674915012476?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,18]],"date-time":"2018-09-18T06:51:25Z","timestamp":1537253485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674915012476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S0091674915012476"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2015.08.023","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725860708.793510798","asserted-by":"object"}]},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Timing and duration of omalizumab response in patients with chronic idiopathic\/spontaneous urticaria","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2015.08.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Mosby, Inc.","name":"copyright","label":"Copyright"}]}}